https://peptide.zone/story/glp-1-long-term-side-effects-varonPeptide Zoneen2026-10-30T04:50:00.000ZDoctor raises GLP 1 long term side effects as evidence on lasting gut symptoms stays thin https://peptide.zone/story/lilly-q3-earnings-mounjaro-zepbound-salesPeptide Zoneen2026-10-30T04:25:00.000ZLilly Q3 earnings top forecasts as Mounjaro and Zepbound sales climb https://peptide.zone/story/lilly-q3-earnings-volume-price-cutsPeptide Zoneen2026-10-30T03:54:00.000ZLilly Q3 earnings show tirzepatide volume outrunning price cuts https://peptide.zone/story/cagrisema-obesityweek-redefine-wegovy-pillPeptide Zoneen2026-10-30T03:26:00.000ZCagriSema ObesityWeek 2026 slate lists REDEFINE 9 and Wegovy pill data but no numbers https://peptide.zone/story/glp-1-thyroid-warning-levothyroxine-timingPeptide Zoneen2026-10-30T03:05:00.000ZGLP 1 thyroid cancer warning covers two rare conditions as pills change levothyroxine timing https://peptide.zone/story/asc30-diabetes-trial-lowers-hba1cPeptide Zoneen2026-10-29T04:26:00.000ZASC30 diabetes trial lowers HbA1c against placebo in 12 week Phase 2 study https://peptide.zone/story/corxel-spac-deal-splits-obesity-strokePeptide Zoneen2026-10-29T03:48:00.000ZCorxel SPAC deal splits obesity pills from stroke drug ahead of CX11 Phase 3 https://peptide.zone/story/hhs-peptide-compounding-policy-bpc-157Peptide Zoneen2026-10-29T03:26:00.000ZHHS peptide compounding policy lets pharmacies make BPC 157 and five other peptides https://peptide.zone/story/peptides-emergency-department-clinician-trainingPeptide Zoneen2026-10-29T02:41:00.000ZPeptides in the emergency department need clinician training says OMED speaker https://peptide.zone/story/retatrutide-ozempic-trial-a1c-weight-lossPeptide Zoneen2026-10-28T22:04:00.000ZRetatrutide Ozempic trial shows bigger A1C drop and double the weight loss https://peptide.zone/story/tradipitant-glp-1-vomiting-phase-3Peptide Zoneen2026-10-28T15:25:00.000ZTradipitant GLP 1 vomiting trial reports 27 percent relative drop in Phase 3 https://peptide.zone/story/glp-1-naion-lawsuits-vision-loss-evidencePeptide Zoneen2026-10-28T15:22:00.000ZGLP 1 NAION lawsuits move ahead as vision loss evidence stays split https://peptide.zone/story/awiqli-pediatric-approval-weekly-insulin-childrenPeptide Zoneen2026-10-28T14:36:00.000ZFDA grants Awiqli pediatric approval as first weekly insulin for children with type 2 diabetes https://peptide.zone/story/retatrutide-sleep-apnea-phase-3-trialsPeptide Zoneen2026-10-28T14:12:00.000ZRetatrutide sleep apnea trials cut breathing pauses in Phase 3 NEJM report